Save Product
Product Details
Synonyms
Lysyl oxidase homolog 2, LOXL2
Source
Biotinylated Human LOXL2, His,Avitag (LO2-H82E3) is expressed from human 293 cells (HEK293). It contains AA Gln 26 - Gln 774 (Accession # Q9Y4K0-1).
Predicted N-terminus: Gln 26
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 87.6 kDa. The protein migrates as 90-110 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Labeling
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
Protein Ratio
Passed as determined by the HABA assay / binding ELISA.
Purity
>90% as determined by SDS-PAGE.
Formulation
Supplied as 0.2 μm filtered solution in 20 mM MES, 50 mM NaCl, pH6.5 with glycerol as protectant.
Contact us for customized product form or formulation.
Shipping and Storage
This product is supplied and shipped on dry ice.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- The product MUST be stored at -70°C or lower upon receipt;
- -70°C for 3 months under sterile conditions.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Biotinylated Human LOXL2, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
Bioactivity
Measured by its ability to produce hydrogen peroxide during the oxidation of benzylamine. The specific activity is >7 pmol/min/μg (QC tested).
Protocol
Customer Reviews Writing Reviews
Background
Recent Advances
Drug Development Progress- English Name：
Lysyl oxidase homolog 2
- Category：
- Approved Drugs：
0 Details
- Drugs in Clinical Trials：
1 Details
- Highest Development Stage：
Phase 2 Clinical
Contact Us
Drug Candidate Licensing
